Gelonghui, January 29丨Capcom Biotech (300639.SZ) announced its 2023 annual performance forecast. Net profit profit attributable to shareholders of listed companies during the reporting period was 13800.00 million yuan to 18.0000 million yuan, down 92.00%-89.57% from the same period last year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 11.95 million yuan - 16.15 million yuan, down 93.11% to 90.69% from the same period last year.
During the reporting period, the company's net profit declined year-on-year, mainly due to changes in industry demand, which led to a decline in demand for the company's related testing products and services, and a sharp year-on-year decline in related business revenue. During the reporting period, the company continued to embrace the national industrial policy, focusing on the fields of maternal and child health, prevention and control of birth defects, early cancer screening and individualized drug testing, and continued to promote the business development of molecular diagnostic products and medical testing services, simultaneously strengthening corporate governance, speeding up the development of new products and strengthening talent development to achieve the company's high-quality development.
During the reporting period, the estimated impact of non-recurring profit and loss on the company's net profit was approximately RMB 18.5 million, mainly government subsidies, investment income, and charitable donations.